Accéder au contenu
MilliporeSigma

Principaux documents

Voir toute la documentation

870273C

Avanti

18:1 Biotinyl Cap PE

Avanti Research™ - A Croda Brand

Synonyme(s) :

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) (sodium salt)

Se connecter pour consulter les tarifs organisationnels et contractuels.

Sélectionner une taille de conditionnement

Changer de vue

A propos de cet article

Formule empirique (notation de Hill) :
C57H102N4O11PNaS
Numéro CAS:
384835-51-2
Poids moléculaire :
1105.47
MDL number:
MFCD22495346
UNSPSC Code:
12352211
NACRES:
NA.25
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aider

Nom du produit

18:1 Biotinyl Cap PE, Avanti Research™ - A Croda Brand 870273C

assay

>99% (TLC)

form

liquid

packaging

pkg of 1 × 2.5 mL (870273C-25mg), pkg of 2 × 4 mL (870273C-200mg)

manufacturer/tradename

Avanti Research™ - A Croda Brand 870273C

concentration

10 mg/mL (870273C-25mg), 25 mg/mL (870273C-200mg)

shipped in

dry ice

storage temp.

−20°C

SMILES string

[H][C@@](COP([O-])(OCCNC(CCCCCNC(CCCC[C@](SC[C@@]1(NC(N2)=O)[H])([C@]12[H])[H])=O)=O)=O)(OC(CCCCCCC/C=C\CCCCCCCC)=O)COC(CCCCCCC/C=C\CCCCCCCC)=O.[Na+]

InChI

1S/C57H103N4O11PS.Na/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-33-41-54(64)69-46-49(72-55(65)42-34-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2)47-71-73(67,68)70-45-44-59-53(63)39-32-31-37-43-58-52(62)40-36-35-38-51-56-50(48-74-51)60-57(66)61-56;/h17-20,49-51,56H,3-16,21-48H2,1-2H3,(H,58,62)(H,59,63)(H,67,68)(H2,60,61,66);/q;+1/p-1/b19-17-,20-18-;/t49-,50+,51+,56+;/m1./s1

InChI key

VQSGNVZURNOPBT-XEAQQBNDSA-M

General description

18:1 Biotinyl Cap PE, also known as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) or DOPE-B-Cap, belongs to a class of head group modified functionalized lipids.

Application

18:1 Biotinyl Cap PE (1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(cap biotinyl) has been used in preparation of liposomes and large unilamellar vesicles (LUV).

Packaging

5 mL Clear Glass Sealed Ampule (870273C-200mg)
5 mL Clear Glass Sealed Ampule (870273C-25mg)

Legal Information

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Still not finding the right product?

Explore all of our products under

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 Oral - STOT SE 3

target_organs

Central nervous system, Liver,Kidney

Classe de stockage

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Hideyo Takatsuki et al.
Nanotechnology, 22(24), 245101-245101 (2011-04-22)
The potential of using actin bundles for the transport of liposomes and single cells across myosin-coated surfaces is investigated. Compared to that observed with filamentous actin, the liposome transport using actin bundles was more linear in nature and able to
David K Y Zhang et al.
Nature protocols, 15(3), 773-798 (2020-01-15)
Synthetic antigen-presenting cells (APCs) are used to mediate scalable ex vivo T-cell expansion for adoptive cell therapy. Recently, we developed APC-mimetic scaffolds (APC-ms), which present signals to T cells in a physiological manner to mediate rapid and controlled T-cell expansion.
Yanqi Yu et al.
ACS nano (2018-11-14)
Understanding the binding of nanoparticles to receptors on biomembranes is critical to the development and screening of therapeutic materials. A prevailing understanding is that multivalent ligand-receptor binding leads to slower and confined translational motion of nanoparticles. In contrast, we report
Afficher tous les articles scientifiques apparentés

Numéro d'article de commerce international

RéférenceGTIN
870273C-25MG04061837668074